1Abu-Duhier FM, Goodeve AC, Wilson GA, et al. Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol, 2001,113:1076-1077.
2Lyman SD, James L, Zappone J, et al. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene, 1993,8:815-822.
3Turner AM, Lin NL, Issarachai S, et al. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood, 1996,88:3383-3390.
4Zhang S, Broxmeyer HE. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem Biophys Res Commun, 2000,277:195-199.
5Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 1996,10:1911-1918.
6Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol, 2000,111:190-195.
7Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol, 2000,108:322-330.
8Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 2001,97:2434-2439, 3589-3595.
9Spiekermann K, Bagrintseva K, Schoch C, et al. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood, 2002,100:3423-3425, 2387-2392.
10Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the MRC 10 and 12 trials. Blood, 2000,96:825.
